Chardan lowered the firm’s price target on uniQure (QURE) to $35 from $38 and keeps a Buy rating on the shares after the company reported Q2 results. The company ended the quarter with cash and equivalents of $377M, supporting a projected operational runway into 2H27, the analyst tells investors in a research note. The firm also noted the company plans to present data in September from the ongoing Phase 1/2 studies of AMT-130 in support of a potential biologics license application submission, including three years of follow-up data for 24 treated patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Mizuho defends uniQure, says factors why it is down are ‘non-issues’
- uniQure’s Strategic Advancements and Regulatory Progress Lead to Buy Rating
- Positive Outlook for uniQure’s AMT-130 Program Amidst Upcoming 3-Year Data Release
- uniQure Announces $200 Million Sales Agreement
- uniQure reports Q2 EPS (69c), consensus (76c)